CAPLIPOINT - Caplin Point Laboratories Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

CAPLIPOINT

68/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹1686.50-21.90(-1.28%)

Market Closed as of Apr 13, 2026, 15:30 IST

Select time range

Pros

Past Returns: Outperforming stock! In past three years, the stock has provided 39.1% return compared to 10.7% by NIFTY 50.

Profitability: Very strong Profitability. One year profit margin are 28%.

Growth: Good revenue growth. With 49.5% growth over past three years, the company is going strong.

Size: Market Cap wise it is among the top 20% companies of india.

Balance Sheet: Strong Balance Sheet.

Smart Money: Smart money has been increasing their position in the stock.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Valuation
Market Cap	12.99 kCr
Price/Earnings (Trailing)	21.16
Price/Sales (Trailing)	5.9
EV/EBITDA	15.37
Price/Free Cashflow	63.57
MarketCap/EBT	16.95
Enterprise Value	12.88 kCr

Fundamentals
Revenue (TTM)	2.2 kCr
Rev. Growth (Yr)	9.9%
Earnings (TTM)	622.13 Cr
Earnings Growth (Yr)	18.4%

Profitability
Operating Margin	35%
EBT Margin	35%
Return on Equity	19.45%
Return on Assets	17.76%
Free Cashflow Yield	1.57%

Growth & Returns
Price Change 1W	9.1%
Price Change 1M	1.1%
Price Change 6M	-16.9%
Price Change 1Y	-0.30%
3Y Cumulative Return	39.1%
5Y Cumulative Return	29.3%
7Y Cumulative Return	23.3%
10Y Cumulative Return	23.1%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-334.73 Cr
Cash Flow from Operations (TTM)	432.37 Cr
Cash Flow from Financing (TTM)	-38.32 Cr
Cash & Equivalents	108.26 Cr
Free Cash Flow (TTM)	240.85 Cr
Free Cash Flow/Share (TTM)	31.69

Balance Sheet
Total Assets	3.5 kCr
Total Liabilities	304.93 Cr
Shareholder Equity	3.2 kCr
Current Assets	2.33 kCr
Current Liabilities	284.9 Cr
Net PPE	523.48 Cr
Inventory	329.43 Cr
Goodwill	0.00

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	1.11 K
Interest/Cashflow Ops	585.28

Dividend & Shareholder Returns
Dividend/Share (TTM)	6
Dividend Yield	0.40%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.20%

Technical Indicators
RSI (14d)	58.34
RSI (5d)	100
RSI (21d)	54.2
MACD Signal	Buy
Stochastic Oscillator Signal	Hold
SharesGuru Signal	Buy
RSI Signal	Hold
RSI5 Signal	Sell
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Buy
SMA 20 Signal	Buy
SMA 50 Signal	Buy
SMA 100 Signal	Buy

Description	Share	Value
Rest of the World	75.1%	432.9 Cr
USA	19.1%	109.8 Cr
Unallocated	5.8%	33.7 Cr
Total		576.5 Cr

Shareholder Name	Holding %
P VIJAYALAKSHMI	24.71%
PAARTHIPAN C C	18.64%
ASHOK GORKEY PARTHEEBAN	11.91%
PARTHEEBAN VIVEK SIDDARTH	11.85%
MAY INDIA PROPERTY PRIVATE LIMITED	2.79%
UTI MULTI CAP FUND	1.77%
FIRST DIMENSION HOLDINGS PRIVATE LIMITED	0.49%
KIRAVIZ PROPERTIES AND CONSULTANCY LLP	0.2%
Other Foreign Institutions	0.03%
VISALATCHI P	0%
CHELLAPPAN POOVALAMBEDU KANDASAMY	0%
KOTTESWARI B	0%
SOUNDARI B	0%

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical Industries	3.97 LCr	58.94 kCr	-9.40%	+0.20%	36.37	6.74	-	-
DRREDDY	Dr. Reddy's Lab	1.03 LCr	36.09 kCr	-7.00%	+12.60%	18.43	2.85	-	-
CIPLA	Cipla	99.34 kCr	29.37 kCr	-7.50%	-13.10%	21.84	3.38	-	-
AUROPHARMA	Aurobindo Pharma	78.37 kCr	33.73 kCr	+3.40%	+27.50%	22.48	2.32	-	-
ALKEM	Alkem Lab	65.04 kCr	14.78 kCr	-1.90%	+12.40%	27.43	4.4	-	-

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	14.4%	1,937	1,694	1,467	1,269	1,061	863
Other Income	43.9%	96	67	56	39	24	41
Total Income	15.5%	2,034	1,761	1,523	1,308	1,085	905
Cost of Materials	3.3%	248	240	223	192	130	108
Purchases of stock-in-trade	3%	576	559	519	397	260	500
Employee Expense	23.8%	178	144	137	115	103	68
Finance costs	-77.3%	0.61	0.78	0.78	0.7	1.59	0.32
Depreciation and Amortization	25%	66	53	45	47	37	32
Other expenses	24.5%	342	275	225	202	158	122
Total Expenses	13.4%	1,357	1,197	1,071	922	771	635
Profit Before exceptional items and Tax	20.1%	677	564	451	386	314	269
Exceptional items before tax	-37%	0	0.27	0.08	0	0	0
Total profit before tax	20.1%	677	564	451	386	314	269
Current tax	22.8%	125	102	82	84	71	62
Deferred tax	1856.5%	10	1.46	-7.94	-6.54	-8.96	-7.46
Total tax	32.4%	136	103	74	77	62	54
Total profit (loss) for period	17.4%	541	461	377	308	251	215
Other comp. income net of taxes	160%	27	11	43	14	-7.16	17
Total Comprehensive Income	20.1%	568	473	420	323	244	232
Earnings Per Share, Basic	17.5%	70.57	60.19	49.62	39.61	32.03	28.42
Earnings Per Share, Diluted	17.6%	70.25	59.9	49.18	39.26	31.71	28.2

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	1.7%	543	534	510	502	493	483
Other Income	13.8%	34	30	23	26	31	21
Total Income	2.1%	576	564	533	528	524	504
Cost of Materials	-3.3%	89	92	74	61	60	69
Purchases of stock-in-trade	5%	128	122	114	139	139	122
Employee Expense	6.5%	50	47	43	47	47	44
Finance costs	2.4%	0.18	0.16	0.18	0.17	0.18	0.21
Depreciation and Amortization	5.9%	19	18	16	17	16	17
Other expenses	1.2%	88	87	94	87	89	85
Total Expenses	2.8%	373	363	349	352	347	335
Profit Before exceptional items and Tax	1.5%	204	201	184	177	177	169
Exceptional items before tax	-	0	0	0	0	0	0
Total profit before tax	1.5%	204	201	184	177	177	169
Current tax	-2.8%	36	37	33	29	34	32
Deferred tax	-57.1%	2.39	4.24	0.6	2.12	2.97	5.19
Total tax	-7.5%	38	41	34	31	37	38
Total profit (loss) for period	3.8%	166	160	151	145	140	131
Other comp. income net of taxes	-66%	17	48	0.36	-1.75	23	1.33
Total Comprehensive Income	-12.1%	183	208	151	144	163	132
Earnings Per Share, Basic	6.4%	21.56	20.32	20.1	18.75	18.28	17.22
Earnings Per Share, Diluted	6.5%	21.51	20.25	20.03	18.69	18.19	17.12

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	20.4%	752	625	529	528	483	528
Other Income	27.6%	135	106	99	57	19	66
Total Income	21.4%	887	731	628	585	501	594
Cost of Materials	-20.5%	137	172	151	156	112	96
Purchases of stock-in-trade	0%	77	77	48	58	83	143
Employee Expense	37.8%	52	38	37	30	27	25
Finance costs	2.2%	0.12	0.1	0.12	0.09	0.17	0.18
Depreciation and Amortization	-7.7%	25	27	26	26	22	20
Other expenses	37.2%	130	95	74	73	47	58
Total Expenses	22%	445	365	334	334	291	341
Profit Before exceptional items and Tax	20.8%	442	366	293	250	210	253
Total profit before tax	20.8%	442	366	293	250	210	253
Current tax	20%	103	86	67	62	55	56
Deferred tax	66.2%	-0.72	-4.09	-7.69	0.82	-1.17	-0.4
Total tax	24.7%	102	82	59	62	54	55
Total profit (loss) for period	19.4%	339	284	234	188	156	198
Other comp. income net of taxes	5.2%	-0.1	-0.16	0.11	0.1	0.22	-0.33
Total Comprehensive Income	19.4%	339	284	234	188	156	197
Earnings Per Share, Basic	20.1%	44.67	37.36	30.89	24.82	20.65	26.13
Earnings Per Share, Diluted	20.1%	44.47	37.18	30.62	24.6	20.45	25.95

Category	CAPLIPOINT	Pharmaceuticals
PE	21.16	33.81
PS	5.90	4.67
Growth	11.4 %	8 %

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-46%	108	199	177	139	138	178
Current investments	19%	370	311	292	238	121	159
Loans, current	-	0	0	0	0	0	0
Total current financial assets	11.2%	1,771	1,593	1,492	1,379	1,332	1,119
Inventories	-2.1%	329	336	327	363	337	288
Total current assets	9.1%	2,328	2,134	1,999	1,892	1,668	1,554
Property, plant and equipment	-1.3%	523	530	452	439	269	267
Capital work-in-progress	27.5%	177	139	153	117	275	220
Non-current investments	-4.7%	266	279	221	138	125	71
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	28.8%	359	279	237	150	131	75
Total non-current assets	9.4%	1,176	1,075	925	805	745	637
Total assets	9.2%	3,504	3,209	2,924	2,697	2,413	2,191
Borrowings, non-current	-	0	0	0	0.92	0	0
Total non-current financial liabilities	528.3%	13	2.91	0.64	11	0.68	0.93
Provisions, non-current	-84.4%	1.05	1.32	9.37	8.61	8.08	7.78
Total non-current liabilities	26.7%	20	16	20	20	16	16
Borrowings, current	-13.3%	0.49	0.55	0.63	0.28	1.9	3.41
Total current financial liabilities	-2.7%	256	263	280	285	267	240
Provisions, current	-26.1%	18	24	19	10	0	0.28
Current tax liabilities	-	-	0	0	0	-	0
Total current liabilities	-6.9%	285	306	329	331	294	268
Total liabilities	-5.3%	305	322	350	351	310	284
Equity share capital	0%	15	15	15	15	15	15
Non controlling interest	11.4%	40	36	32	31	29	27
Total equity	10.8%	3,199	2,886	2,575	2,347	2,102	1,907
Total equity and liabilities	9.2%	3,504	3,209	2,924	2,697	2,413	2,191

Description	(%) Q/Q	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023
Cash and cash equivalents	-30.3%	70	100	83	81	70	122
Current investments	23.2%	383	311	282	238	121	159
Loans, current	-	0	0	0	13	0	71
Total current financial assets	16%	843	727	690	595	593	590
Inventories	-9.2%	60	66	71	86	57	52
Total current assets	14.3%	944	826	787	702	674	664
Property, plant and equipment	6%	214	202	172	162	152	152
Capital work-in-progress	-10%	19	21	17	28	36	43
Non-current investments	62.2%	796	491	432	346	334	275
Loans, non-current	-100.4%	0	246	242	263	214	156
Total non-current financial assets	6.4%	804	756	686	619	551	433
Total non-current assets	5.3%	1,041	989	883	820	754	639
Total assets	9.4%	1,984	1,814	1,670	1,522	1,427	1,303
Total non-current financial liabilities	-	2.43	0	0.2	0.16	0.43	0.48
Provisions, non-current	-493.3%	0.11	0.85	0	0	0	0
Total non-current liabilities	-7.7%	13	14	17	13	25	16
Borrowings, current	-	0	0	0	0	0	0
Total current financial liabilities	1.3%	78	77	92	99	120	103
Provisions, current	20%	13	11	12	4.42	0.02	0.17
Current tax liabilities	-	0	-	0	0	-	0
Total current liabilities	28.3%	128	100	118	119	137	147
Total liabilities	23.9%	141	114	135	132	161	163
Equity share capital	0%	15	15	15	15	15	15
Total equity	8.4%	1,844	1,701	1,535	1,390	1,266	1,140
Total equity and liabilities	9.4%	1,984	1,814	1,670	1,522	1,427	1,303

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Finance costs	-77.3%	0.61	0.78	0.78	0.7	-	-
Change in inventories	134.3%	27	-74.82	-60.9	-48.31	-	-
Depreciation	25%	66	53	45	47	-	-
Unrealised forex losses/gains	-139.8%	-3.46	-0.86	-1.18	0.04	-	-
Adjustments for interest income	37%	64	47	35	24	-	-
Share-based payments	-566.7%	0	0.85	5.19	6.67	-	-
Net Cashflows from Operations	32.9%	563	424	363	418	-	-
Income taxes paid (refund)	20.4%	131	109	88	82	-	-
Other inflows (outflows) of cash	78.5%	0	-3.66	-3.15	0	-	-
Net Cashflows From Operating Activities	39%	432	311	272	337	-	-
Purchase of property, plant and equipment	31.7%	192	146	194	91	-	-
Purchase of investment property	-	0	0	0	77	-	-
Interest received	18.6%	52	44	27	20	-	-
Other inflows (outflows) of cash	115.3%	19	-116.78	90	-122.83	-	-
Net Cashflows From Investing Activities	-7%	-334.73	-312.63	-217.86	-270.94	-	-
Proceeds from exercise of stock options	0%	0.01	0.01	0.02	0	-	-
Proceeds from borrowings	82.3%	0.27	-3.13	2.91	0	-	-
Repayments of borrowings	-	0	0	0	17	-	-
Dividends paid	12.1%	38	34	30	23	-	-
Interest paid	-77.3%	0.61	0.78	0.78	0.7	-	-
Other inflows (outflows) of cash	-	0	0	0	-0.76	-	-
Net Cashflows from Financing Activities	-0.6%	-38.32	-38.07	-28.17	-40.71	-	-
Effect of exchange rate on cash eq.	-614.3%	0	0.86	1.18	-0.09	-	-
Net change in cash and cash eq.	245.5%	59	-38.86	27	25	-	-

Description	(%) Q/Q	Dec-2025	Sep-2025	Jun-2025	Mar-2025	Dec-2024	Sep-2024
Revenue From Operations	8%	189	175	183	174	185	208
Other Income	-46.6%	32	59	32	41	29	43
Total Income	-5.6%	221	234	215	215	214	251
Cost of Materials	11.8%	39	35	39	34	33	33
Purchases of stock-in-trade	10%	23	21	13	17	19	24
Employee Expense	9.1%	13	12	9.63	14	14	13
Finance costs	2.1%	0.07	0.05	0.04	0.04	0.04	0.02
Depreciation and Amortization	7%	6.37	6.02	6.14	6.09	6.01	6.49
Other expenses	-10.3%	27	30	28	29	33	35
Total Expenses	-1%	104	105	102	105	114	116
Profit Before exceptional items and Tax	-9.4%	117	129	112	110	100	135
Total profit before tax	-9.4%	117	129	112	110	100	135
Current tax	7.7%	29	27	27	24	26	29
Deferred tax	54.4%	0.38	-0.36	-0.34	0.03	-0.09	-0.23
Total tax	16%	30	26	27	24	25	29
Total profit (loss) for period	-15.7%	87	103	86	86	75	106
Other comp. income net of taxes	-188%	-0.44	0.5	0	-0.22	0	0.12
Total Comprehensive Income	-15.7%	87	103	86	86	75	106
Earnings Per Share, Basic	-16.1%	11.49	13.5	11.3	11.37	9.83	13.92
Earnings Per Share, Diluted	-16%	11.46	13.45	11.26	11.35	9.77	13.85

CAPLIPOINT - Caplin Point Laboratories Ltd. Share Price

CAPLIPOINT

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

CAPLIPOINT

CAPLIPOINT - Caplin Point Laboratories Ltd. Share Price

CAPLIPOINT

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

CAPLIPOINT

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Caplin Point Laboratories Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Caplin Point Laboratories Ltd. do?

Important Disclosure & Data Context